NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SANOFI · data 2026-10-31
Sanofi India Limited
In plain words
Price: 33.7% below its 52-week high of ₹4,832.
Delivery: 46.1% of traded shares were kept for delivery over the last 10 sessions, against 56.2% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,822 cr |
| Net profit (last 12 months) | ₹365 cr |
| Sales growth, 3 years (yearly) | -12.8% |
| Profit growth, 3 years (yearly) | -19.3% |
At a glance
Promoters 60.4% (unchanged in a year), pledged 0.0%, institutions 25.1%.
P/E 20.2, dividend yield 3.8%. Price relative to earnings and book value (low is cheaper, not better).
ROE 40.6%, ROCE 54.6%, operating margin 26.3%: how much profit it earns on the money it uses.
Debt/equity 0.02, Profit growth -19.3% and sales growth -12.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (40.6%).
- Healthy operating margin (26.3%).
- Pays a dividend yielding 3.8%.
- Profit fell 19.3% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
27/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 37.0% over the last 20 sessions vs 55.4% in the 40 before (0.67x); shares delivered per day 1.01x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 2 schemes hold it, about ₹195 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 61/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend
- 24 Sept 26Deal Block deal: SANOFI HEALTHCARE INDIA PRIVATE LIM… bought ₹1,068.2 cr (net ₹0 cr) +2.9% next session
- 22 Apr 26Dividend Dividend ₹48 (ex-date) -3.9% next session
- 7 Nov 25Dividend Dividend ₹75 (ex-date) -3.1% next session
- 25 Apr 25Dividend Dividend ₹117 (ex-date) -7.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% |
| Foreign institutions (FII) | 5.73% | 5.69% | 5.64% | 5.55% |
| Domestic institutions (DII) | 19.41% | 19.87% | 21.13% | 21.31% |
| Mutual funds | 8.62% | 9.14% | 9.26% | 9.46% |
| Retail investors | 11.50% | 11.05% | 9.87% | 9.69% |
| Number of shareholders | 80,089 | 80,005 | 75,758 | 75,813 |
Common questions
How much do promoters hold in Sanofi India Limited?
Promoters held 60.40% of Sanofi India Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sanofi India Limited debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Sanofi India Limited's P/E ratio?
About 20.2, based on the last 12 months' earnings and a price of ₹3,204.1 (data 2026-10-31).
What is the 52-week high and low of Sanofi India Limited?
The 52-week high is ₹4,832 and the 52-week low is ₹2,758.2.
Mutual funds holding Sanofi India Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹195 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE LARGE CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.37% | ₹103 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.00% | ₹92 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sanofi India Limited | ₹3,204.1 | ₹7,380 cr | 20.2 | — | 40.6% | 54.6% | 0.02 | -33.2% |
| Aarti Pharmalabs Limited | ₹872.7 | ₹7,922 cr | 30.9 | 3.5 | 8.5% | 11.5% | 0.36 | +4.9% |
| Sanofi Consumer Healthcare India Limited | ₹3,442.3 | ₹7,911 cr | 28.3 | — | 73.1% | 82.8% | 0.06 | -26.8% |
| Suven Life Sciences Limited | ₹258.85 | ₹7,293 cr | — | — | -78.8% | -80.8% | 0.03 | +33.2% |
| Bliss GVS Pharma Limited | ₹647.5 | ₹6,894 cr | 51.4 | — | 11.5% | 10.9% | 0.02 | +325.8% |
| Supriya Lifescience Limited | ₹847.3 | ₹6,810 cr | 34.4 | — | 19.1% | 22.3% | 0 | +13.4% |
Compare SANOFI with AARTIPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SANOFI in NSE Scanner →